2024-514496-18-01CompletedPhase 1
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Jan 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 29 Oct 2024
- Start date
- 30 Jan 2025
- Lead sponsor
- Disruptive Pharma AB
- EU CT number
- 2024-514496-18-01
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 12
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CTC Clinical Trial Consultants AB | Uppsala | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.